Liraglutide - Generic Drug Details

What are the generic drug sources for liraglutide and what is the scope of patent protection?

Liraglutide is the generic ingredient in three branded drugs marketed by Hikma, Lupin Ltd, Nanjing King Friend, Orbicular, Teva Pharms, Novo, and Novo Nordisk Inc, and is included in seven NDAs. There are two patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Liraglutide has sixty-three patent family members in twenty-seven countries.

There are seven drug master file entries for liraglutide. Eleven suppliers are listed for this compound.

Summary for liraglutide

International Patents:	63
US Patents:	2
Tradenames:	3
Applicants:	7
NDAs:	7
Drug Master File Entries:	7
Finished Product Suppliers / Packagers:	11
Clinical Trials:	455
Patent Applications:	6,609
Drug Prices:	Drug price trends for liraglutide
What excipients (inactive ingredients) are in liraglutide?	liraglutide excipients list
DailyMed Link:	liraglutide at DailyMed

See drug prices for liraglutide

Recent Clinical Trials for liraglutide

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
The Fourth Affiliated Hospital of Zhejiang University School of Medicine	PHASE4
Novo Nordisk A/S	PHASE1
Karolinska Institutet	NA

See all liraglutide clinical trials

Pharmacology for liraglutide

Drug Class	GLP-1 Receptor Agonist
Mechanism of Action	Glucagon-like Peptide-1 (GLP-1) Agonists

Anatomical Therapeutic Chemical (ATC) Classes for liraglutide

A10BJ	Glucagon-like peptide-1 (GLP-1) analogues
A10B	BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
A10	DRUGS USED IN DIABETES
A	Alimentary tract and metabolism

Paragraph IV (Patent) Challenges for LIRAGLUTIDE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
SAXENDA	Injection	liraglutide	18 mg/3 mL prefilled syringe	206321	1	2021-08-16
VICTOZA	Injection	liraglutide	18 mg/3 mL prefilled syringe	022341	1	2016-12-12

US Patents and Regulatory Information for liraglutide

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Novo Nordisk Inc	VICTOZA	liraglutide	SOLUTION;SUBCUTANEOUS	022341-001	Jan 25, 2010	AP1	RX	Yes	Yes	9,968,659*PED				Y
Novo	SAXENDA	liraglutide	SOLUTION;SUBCUTANEOUS	206321-001	Dec 23, 2014	AP2	RX	Yes	Yes	8,114,833*PED				Y
Novo Nordisk Inc	VICTOZA	liraglutide	SOLUTION;SUBCUTANEOUS	022341-001	Jan 25, 2010	AP1	RX	Yes	Yes	8,114,833*PED				Y
Teva Pharms	LIRAGLUTIDE	liraglutide	SOLUTION;SUBCUTANEOUS	214568-001	Aug 27, 2025	AP2	RX	No	No
Novo	SAXENDA	liraglutide	SOLUTION;SUBCUTANEOUS	206321-001	Dec 23, 2014	AP2	RX	Yes	Yes	9,968,659*PED				Y

Expired US Patents for liraglutide

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Novo Nordisk Inc	VICTOZA	liraglutide	SOLUTION;SUBCUTANEOUS	022341-001	Jan 25, 2010	7,235,627
Novo	SAXENDA	liraglutide	SOLUTION;SUBCUTANEOUS	206321-001	Dec 23, 2014	10,357,616
Novo Nordisk Inc	VICTOZA	liraglutide	SOLUTION;SUBCUTANEOUS	022341-001	Jan 25, 2010	6,004,297
Novo Nordisk Inc	VICTOZA	liraglutide	SOLUTION;SUBCUTANEOUS	022341-001	Jan 25, 2010	RE41956*PED
Novo	SAXENDA	liraglutide	SOLUTION;SUBCUTANEOUS	206321-001	Dec 23, 2014	7,235,627

International Patents for liraglutide

Country	Patent Number	Title	Estimated Expiration
World Intellectual Property Organization (WIPO)	2005049061
Spain	2893755
Portugal	3423082
Russian Federation	2745604	ЛИРАГЛУТИД ПРИ СЕРДЕЧНО-СОСУДИСТЫХ СОСТОЯНИЯХ (LYRAGLUTIDE FOR CARDIOVASCULAR DISEASE)
China	1882356	Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices

Supplementary Protection Certificates for liraglutide

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2209800	132014902311502	Italy		PRODUCT NAME: INSULINA DEGLUDEC/LIRAGLUTIDE(XULTOPHY); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/14/947, 20140918
2209800	122014000114	Germany		PRODUCT NAME: KOMBINATION VON INSULIN DEGLUDEC UND LIRAGLUTIDE; REGISTRATION NO/DATE: EU/1/14/947 20140918
2209800	SPC/GB14/079	United Kingdom		PRODUCT NAME: COMBINATION OF INSULIN DEGLUDEC, OR PHARMACEUTICALLY ACCEPTABLE SOLVATES, HYDRATES, OR SALTS THEREOF, AND LIRAGLUTIDE, OR PHARMACEUTICALLY ACCEPTABLE SOLVATES, HYDRATES, OR SALTS THEREOF; REGISTERED: CH 65041 20140912; UK EU/1/14/947 20140922
2209800	14C0085	France		PRODUCT NAME: LIRAGLUTIDE ET INSULINE DEGLUDEC; REGISTRATION NO/DATE: EU/1/14/947 20140918
2597103	2017/015	Ireland		PRODUCT NAME: COMBINATION OF INSULIN DEGLUDEC AND LIRAGLUTIDE; NAT REGISTRATION NO/DATE: EU/1/14/947 20140918; FIRST REGISTRATION NO/DATE: 65041 20140912

Market Dynamics and Financial Trajectory for Liraglutide

Last updated: March 12, 2026

What is the Current Market Position of Liraglutide?

Liraglutide is a GLP-1 receptor agonist approved for type 2 diabetes management and obesity treatment. It is marketed under brands including Victoza (diabetes) and Saxenda (weight management). Developed by Novo Nordisk, liraglutide has gained market approval in over 80 countries, with global sales surpassing USD 5.5 billion in 2022 [1].

What Are the Key Market Drivers?

Increasing Prevalence of Type 2 Diabetes: The International Diabetes Federation estimates 537 million adults worldwide have diabetes, projected to reach 643 million by 2030 [2]. Obesity rates mirror this trend, fueling demand.

Efficacy in Glycemic and Weight Control: Liraglutide demonstrates superior HbA1c reduction and weight loss compared to other treatments. Its once-daily dosing improves patient compliance.

Regulatory Approvals and Label Expansion: In 2022, the FDA approved higher doses of Saxenda for obesity, extending liraglutide's market potential. The European Medicines Agency also approved expanded indications.

Development of Fixed-Dose Combinations: Combinations with other antidiabetics, such as insulin, enhance therapeutic options, expanding liraglutide’s application scope.

Shift Toward Patient-Centric Therapies: Preference for injectable therapies with proven efficacy shapes market adoption.

How Do Competition and Patent Status Affect the Market?

Competitive Landscape: Semaglutide (Wegovy, Ozempic) and dulaglutide (Trulicity) are primary competitors. Semaglutide's weekly dosing and higher efficacy in weight loss have challenged liraglutide's market share [3].

Patent Expiry and Biosimilar Development: Novo Nordisk’s patent for Victoza expires in 2027. Patent challenges and biosimilar entry could lower prices and erode market momentum.

What are the Financial Trajectories and Growth Projections?

Revenue Trends: Post-2016 launch of Saxenda, liraglutide revenues grown at an average annual rate of 15%. Sales peaked at USD 5.5 billion in 2022, with projections to reach USD 7 billion by 2025 if no significant market disruptions occur [4].

Market Penetration Strategies: Novo Nordisk invests in expanding access in emerging markets, where obesity and diabetes prevalence rise rapidly. Launch of new formulations, such as microgram-scale injections, aims to improve adherence.

Pricing and Reimbursement Trends: In high-income countries, reimbursement remains favorable, supporting premium pricing for liraglutide. In emerging markets, price adjustments are underway to penetrate broader populations.

Impact of Biosimilars: Entry anticipated post-2027 could reduce prices by 20–40%, pressuring revenue growth.

What Regulatory and Policy Factors Influence Market and Financial Outcomes?

Approval Timelines: Rapid approval processes in major markets accelerate revenue realization. Delays or rejections can limit growth.

Medication Guidelines: Inclusion in recent ADA/EASD guidelines as a preferred agent underpins sustained demand [5].

Reimbursement Policies: Reimbursement coverage is critical. Favorable policies directly influence patient access and sales.

Patent Litigation and Copyright Laws: Patent disputes and legal challenges can delay biosimilar entry, affecting revenue trajectories.

Conclusion

Liraglutide maintains a strong market position driven by rising diabetes and obesity prevalence, product efficacy, and regulatory support. Competition from semaglutide, impending patent expirations, and biosimilar development pose risks. Revenue growth remains robust but is susceptible to pricing pressures and policy changes. Tailored strategies focusing on emerging markets, formulation innovations, and leveraging guideline endorsements will be critical for sustaining long-term financial performance.

---

Key Takeaways

• Liraglutide's 2022 sales exceeded USD 5.5 billion; projected to reach USD 7 billion by 2025.
• Competition from semaglutide and upcoming biosimilars will challenge market share.
• Patent expiration in 2027 may lead to biosimilar entry, reducing prices and margins.
• Regulatory approvals and reimbursement policies significantly influence sales trajectories.
• Expanding indications and formulation improvements will support continued growth.

---

FAQs

1. How does liraglutide compare to semaglutide in terms of efficacy?
Semaglutide generally shows higher efficacy in weight loss and HbA1c reduction, especially with weekly dosing, which has led to increased market share.

2. What is the timeline for biosimilar entry?
Biosimilars are expected post-2027, following patent expiration. Market entry and pricing will depend on generic approval timelines.

3. Are there new formulations of liraglutide under development?
Yes, efforts include developing auto-injectors with simplified dosing and combination therapies to improve compliance.

4. How does reimbursement impact liraglutide sales?
Favorable reimbursement policies in high-income countries sustain premium pricing and access, supporting revenue growth.

5. What emerging markets hold significant potential for liraglutide?
India, China, and Southeast Asian nations are expanding markets due to rising diabetes and obesity rates, with tailored pricing strategies.

---

References

[1] Novo Nordisk. (2023). Annual report 2022. https://www.novonordisk.com/investors/annual-report.html

[2] International Diabetes Federation. (2022). IDF Diabetes Atlas, 10th edition.

[3] European Society of Cardiology. (2022). GLP-1 receptor agonists in clinical practice: Semaglutide vs. Liraglutide.

[4] MarketWatch. (2023). Liraglutide market forecast and analysis.

[5] American Diabetes Association. (2022). Standards of Medical Care in Diabetes—2022.

---